Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 5.09% based on its latest 2018Q1 regulatory filing with the SEC. Bvf Inc sold 386,100 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 7.20 million shares of the health care company at the end of 2018Q1, valued at $97.94M, down from 7.59 million at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $611.43M market cap company. The stock increased 1.88% or $0.23 during the last trading session, reaching $12.44. About 65,676 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since June 14, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 ChemoCentryx 4Q EPS 80c; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En
Ken Griffin decreased its stake in National Oilwell Varco Inc (Put) (NOV) by 60.73% based on its latest 2018Q1 regulatory filing with the SEC. Citadel Advisors Llc sold 136,100 shares as the company’s stock rose 14.04% while stock markets declined. The hedge fund run by Ken Griffin held 88,000 shares of the energy company at the end of 2018Q1, valued at $3.24 million, down from 224,100 at the end of the previous reported quarter. Citadel Advisors Llc who had been investing in National Oilwell Varco Inc (Put) for a number of months, seems to be less bullish one the $16.04 billion market cap company. The stock decreased 0.62% or $0.26 during the last trading session, reaching $41.99. About 304,892 shares traded. National Oilwell Varco, Inc. (NYSE:NOV) has risen 26.56% since June 14, 2017 and is uptrending. It has outperformed by 13.99% the S&P500. Some Historical NOV News: 16/04/2018 – National Oilwell Varco Provides Operational Update for the 1Q 2018; 27/04/2018 – NOV: SAW EXPLORERS DEPLOY DRILL PIPE FROM STACKED RIGS IN 1Q; 16/04/2018 – National Oilwell Varco: Optimistic About 2Q, Rest of Year; 16/04/2018 – National Oilwell Varco Sees 1Q Adjusted Ebitda About $160M; 16/04/2018 – NATIONAL OILWELL VARCO PRELIM 1Q ADJ. EBITDA ABOUT $160M; 04/05/2018 – National Oilwell at MUFG Securities Houston Energy Tour May 14; 26/04/2018 – NATIONAL OILWELL VARCO INC NOV.N – BACKLOG FOR CAPITAL EQUIPMENT ORDERS FOR RIG TECHNOLOGIES AT MARCH 31, 2018 WAS $2.05 BLN; 27/04/2018 – NATIONAL OILWELL SEES CLOSING SEVERAL M&A DEALS IN 2Q; 26/04/2018 – National Oilwell Varco 1Q Loss $68M; 11/05/2018 – National Oilwell Varco Declares Dividend of 5c
Citadel Advisors Llc, which manages about $181.79B US Long portfolio, upped its stake in Ishares Tr (IEZ) by 75,714 shares to 84,714 shares, valued at $2.75 million in 2018Q1, according to the filing. It also increased its holding in Iridium Communications Inc (Call) (NASDAQ:IRDM) by 30,800 shares in the quarter, for a total of 53,400 shares, and has risen its stake in 2U Inc (Call) (NASDAQ:TWOU).
Analysts await National Oilwell Varco, Inc. (NYSE:NOV) to report earnings on July, 26 after the close. They expect $0.02 earnings per share, up 114.29% or $0.16 from last year’s $-0.14 per share. NOV’s profit will be $7.64M for 524.88 P/E if the $0.02 EPS becomes a reality. After $-0.18 actual earnings per share reported by National Oilwell Varco, Inc. for the previous quarter, Wall Street now forecasts -111.11% EPS growth.
Among 36 analysts covering National Oilwell Varco (NYSE:NOV), 8 have Buy rating, 5 Sell and 23 Hold. Therefore 22% are positive. National Oilwell Varco had 125 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Hold” rating by Societe Generale on Thursday, April 19. The company was maintained on Tuesday, December 19 by Piper Jaffray. The rating was upgraded by Loop Capital on Thursday, August 17 to “Buy”. The stock has “Sell” rating by BMO Capital Markets on Wednesday, October 11. As per Monday, October 30, the company rating was maintained by Barclays Capital. The firm earned “Hold” rating on Friday, October 6 by RBC Capital Markets. The rating was maintained by Jefferies on Wednesday, February 7 with “Hold”. The company was upgraded on Tuesday, June 20 by PiperJaffray. The company was downgraded on Tuesday, April 17 by B. Riley & Co. On Wednesday, March 9 the stock rating was maintained by Susquehanna with “Neutral”.
Investors sentiment increased to 0.86 in Q1 2018. Its up 0.16, from 0.7 in 2017Q4. It is positive, as 42 investors sold NOV shares while 182 reduced holdings. 54 funds opened positions while 138 raised stakes. 354.58 million shares or 1.45% more from 349.52 million shares in 2017Q4 were reported. Alpha Windward Lc invested in 0.01% or 608 shares. Wells Fargo Mn accumulated 5.35M shares. Lsv Asset reported 1.78 million shares. Summit Asset Mngmt Ltd Com holds 0.15% of its portfolio in National Oilwell Varco, Inc. (NYSE:NOV) for 8,468 shares. Adams Natural Fund holds 0.84% or 141,900 shares in its portfolio. Manufacturers Life The owns 2.88M shares or 0.12% of their US portfolio. 39.62 million were accumulated by Vanguard Grp Incorporated. Advisor Partners Ltd Liability, California-based fund reported 6,832 shares. Smithfield Trust holds 0% or 90 shares in its portfolio. Segall Bryant And Hamill Limited Liability holds 46,216 shares or 0.04% of its portfolio. Legal & General Group Public Ltd Llc invested in 0.06% or 2.05M shares. Moreover, Marathon Asset Mngmt Llp has 0.84% invested in National Oilwell Varco, Inc. (NYSE:NOV) for 1.48 million shares. Td Asset Management Inc holds 118,474 shares. Rbf Ltd Company owns 0.07% invested in National Oilwell Varco, Inc. (NYSE:NOV) for 15,000 shares. Wealthfront Inc holds 0.01% or 30,176 shares.
Since February 28, 2018, it had 0 buys, and 3 selling transactions for $2.14 million activity. Weinstock Craig L. sold $220,165 worth of National Oilwell Varco, Inc. (NYSE:NOV) on Monday, May 21.
Another recent and important National Oilwell Varco, Inc. (NYSE:NOV) news was published by Seekingalpha.com which published an article titled: “National Oilwell Varco buys Dutch rig design and engineering firm” on June 01, 2018.
Investors sentiment decreased to 1 in 2018 Q1. Its down 0.30, from 1.3 in 2017Q4. It is negative, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Spark Inv Management Ltd reported 62,600 shares stake. Renaissance Tech Llc holds 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 769,281 shares. Carmignac Gestion holds 390,097 shares. California Public Employees Retirement System holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 62,800 shares. Moreover, Ellington Management Gru Ltd Liability has 0.02% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Banque Pictet And Cie Sa, Switzerland-based fund reported 54,178 shares. 79,000 are held by Clarivest Asset Management Lc. Proshare Advisors Ltd Liability owns 25,705 shares for 0% of their portfolio. Thompson Davis Com Inc, Virginia-based fund reported 625 shares. Alps Incorporated reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Massachusetts-based Bogle Inv Mgmt Ltd Partnership De has invested 0.02% in ChemoCentryx, Inc. (NASDAQ:CCXI). Fernwood Mngmt Limited Liability invested in 0.08% or 10,000 shares. Credit Suisse Ag accumulated 0% or 13,269 shares. Voya Mgmt Ltd Llc, Georgia-based fund reported 12,285 shares. Bnp Paribas Arbitrage Sa owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 5,362 shares.
Since May 1, 2018, it had 0 insider buys, and 8 sales for $6.04 million activity. Schall Thomas J. had sold 92,798 shares worth $1.19M. Cappel Markus J. also sold $35,217 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares.
Among 6 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 1 Hold. Therefore 67% are positive. ChemoCentryx had 8 analyst reports since September 3, 2015 according to SRatingsIntel. The company was downgraded on Monday, September 21 by Zacks. JP Morgan maintained it with “Overweight” rating and $16 target in Tuesday, March 13 report. The stock has “Hold” rating by Cowen & Co on Tuesday, August 8. On Tuesday, February 21 the stock rating was initiated by JMP Securities with “Mkt Outperform”. The firm earned “Buy” rating on Thursday, August 10 by JMP Securities. The firm earned “Sell” rating on Thursday, September 3 by Zacks.
More recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx to Present at Two Upcoming Investor Conferences” on May 30, 2018. Also Nasdaq.com published the news titled: “Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open …” on June 04, 2018. Globenewswire.com‘s news article titled: “ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress” with publication date: May 23, 2018 was also an interesting one.
Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 14. They expect $-0.25 EPS, down 31.58% or $0.06 from last year’s $-0.19 per share. After $-0.19 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 31.58% negative EPS growth.
Bvf Inc, which manages about $999.89 million and $986.48M US Long portfolio, upped its stake in Verastem Inc (NASDAQ:VSTM) by 487,000 shares to 2.74M shares, valued at $8.16 million in 2018Q1, according to the filing. It also increased its holding in Forward Pharma A/S by 1.30M shares in the quarter, for a total of 4.76 million shares, and has risen its stake in Pieris Pharmaceuticals Inc.